Protracted COVID-19 pneumonitis early post-ABO incompatible kidney transplantation: Management considerations and the role of whole genome sequencing.
ABO incompatible
COVID-19
antiviral
kidney transplant
pneumonitis
Journal
Nephrology (Carlton, Vic.)
ISSN: 1440-1797
Titre abrégé: Nephrology (Carlton)
Pays: Australia
ID NLM: 9615568
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
11
08
2023
received:
17
07
2023
accepted:
15
08
2023
medline:
3
10
2023
pubmed:
28
8
2023
entrez:
27
8
2023
Statut:
ppublish
Résumé
We present the case of a recent ABO incompatible kidney transplant recipient with persistent SARS-CoV-2 infection and pneumonitis. Serial whole genome sequencing confirmed intra-host viral evolution, which was used as a surrogate to confirm active viral replication and support re-treatment with antivirals, late in the course of infection. A prolonged course of remdesivir combined with immunosuppression modulation resulted in successful clearance of virus and clinical improvement. The diagnostic process undertaken in this case provides a useful guide for other clinicians when approaching similar patients.
Substances chimiques
ABO Blood-Group System
0
Antiviral Agents
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
639-643Informations de copyright
© 2023 Asian Pacific Society of Nephrology.
Références
Choi B, Choudhard M, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291-2293.
Stanford University. SARS-CoV-2 Sequence Analysis. https://covdb.stanford.edu/sierra/sars2/by-sequences/. Accessed 11 January 2022
Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215-220.
Rydynski Morderbacher C, Ramirez S, Dan J, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996-1012.
Sanderson T, Hisner R, Donovan-Banfield I, et al. Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases. medRXiv. 2023;01(26):23284998.
Zeng C, Evans J, King T, Liu S. SARS-CoV-2 spreads through cell-to-cell transmission. PNAS. 2021;119:e2111400119.
‘Standord University’. Coronavirus Antiviral and Resistance Database. 2023 https://covdb.stanford.edu/susceptibility-data/table-mab-susc/. Accessed 3 March 2023
Boucau J, Marino C, Regan J, et al. Duration of shedding of culturable virus in SARS-CoV-2 omicron (BA.1) infection. N Engl J Med. 2022;387:2022-2024.
Bailly B, Pere H, Veyer D, et al. Persistent coronavirus disease 2019 (COVID-19) in an immunocompromised host treated by severe acute resporatory coronavirus 2 (SARS-CoV-2) specific monoclonal antibodies. Clin Infect Dis. 2022;71:1706-1707.
Hogan JI, Duerr R, Dimartino D, et al. Remdesivir resistance in transplant recipients with persistent coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2023;76:342-345.
Israelow B, Mao T, Klein J, et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci Immunol. 2021;6:6.
Roberts MB, Fishman JA. Immunosuppressive agents and infectious risk in transplantation: managing the “net state of immunosuppression”. Clin Infect Dis. 2021;73:1302-1317.
Pinchera B, Spirito L, Buonomo A, et al. mTOR inhibitor use is associated with a favorable outcome of COVID-19 in patients of kidney transplant: results of a retrospective study. Front Med. 2022;9:9.
Marinelli T, Ferreira VH, Ierullo M, et al. Prospective clinical, virologic and immunologic assessment of COVID-19 in transplant recipients. Transplantation. 2021;105(10):2175-2183.
Baas M, Struijk G, Moes D. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int. 2014;27:428-436.